Novo Nordisk says launch of weight loss drug Wegovy in new markets delayed due to US demandProactive Investors • 06/20/23
Novo Nordisk takes actions to help protect US patients from unlawful sales of non-FDA approved medicines claiming to contain semaglutidePRNewsWire • 06/20/23
Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst saysMarket Watch • 06/20/23
Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, DenmarkGlobeNewsWire • 06/12/23
3 Reasons Why Growth Investors Shouldn't Overlook Novo Nordisk (NVO)Zacks Investment Research • 06/09/23
Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 06/05/23
Novo Nordisk's Smash-Hit Drug Could Become Even More Profitable. Here's Why.The Motley Fool • 06/05/23
Novo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining sharesGlobeNewsWire • 06/05/23
Novo Nordisk Enters Into Exclusive Negotiations to Acquire a Controlling Stake in BICORP, to Be Followed by a Tender Offer on All Remaining Shares.Business Wire • 06/05/23